1
Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma
Condition(s):Glioma, Malignant; Gliosarcoma; Astrocytoma of BrainLast Updated:September 17, 2019Unknown status
Temozolomide: 1081 Clinical Trials, Page 1 of 109
Hide Studies Not Open or Pending
2
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)
Condition(s):Breast Cancer Triple NegativeLast Updated:July 19, 2022Not yet recruiting
3
First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and/or Radiological Infiltrative Pattern of Progression
Condition(s):Adult Brainstem GliomaLast Updated:September 10, 2021Recruiting
4
5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme
Condition(s):Glioblastoma MultiformeLast Updated:November 19, 2021Completed
5
A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)
Condition(s):Lung Neuroendocrine Neoplasm; GEP Neuroendocrine TumorLast Updated:October 13, 2021Recruiting
6
Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial
Condition(s):Anaplastic Oligodendroglioma; Anaplastic OligoastrocytomaLast Updated:April 26, 2016Completed
7
Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic
Condition(s):Extensive Stage Small Cell Lung CancerLast Updated:November 23, 2016Unknown status
8
Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)
Condition(s):Glioma; GlioblastomaLast Updated:October 8, 2020Unknown status
9
Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study
Condition(s):Neuroendocrine Tumors; Frailty; Chemotherapy EffectLast Updated:September 26, 2022Recruiting
10
Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas
Condition(s):Neuroendocrine CarcinomasLast Updated:October 26, 2020Completed